

**T
I
T
L
E**

P

rHADLIMA™

A
d
a
l
i
m
u
m
a
b
i
n
j
e
c
t
i
o
n

4
0
m
g
i
n
0
.

8
m
L
s
t
e
r
i
l
e
s
o
l
u
t
i
o
n
(
5
0
m
g
/
m
L
)
,
p
r
e
-
f
i
l
l
e

d
s
y
r
i
n
g
e
f
o
r
s
u
b
c
u
t
a
n
e
o
u
s
i
n
j
e
c
t
i
o
n

P

rHADLIMA™

A

d
a
l
i
m
u
m
a
b
i
n
j
e
c
t
i
o
n

4
0
m
g
i
n
0
.
8
m
L
s
t
e
r
i
l
e

s
o
l
u
t
i
o
n
(
5
0
m
g
/
m
L
)
,
a
u
t
o
-
i
n
j
e
c
t
o
r
f
o
r
s
u
b

C
u
t
a
n
e
o
u
s
i
n
j
e
c
t
i
o
n

H
A
D
L
I
M

jection) is a biosimilar biologic drug (biosimilar) to

H
u
m
i
r
a
®
.

B

i
o
l
o
g
i
c
a
l
R
e
s
p
o
n
s
e
M
o
d
i
f
i
e
r

H
A
D
L
I
M

ATM or

H
A

D
L
I
M

ATM

P
u
s
h
T
o
u
c

C
O
M
P
A

juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease

H
A
D
L
I
M

N
Y
N
A
M
E
A
N
D
A
D
D
R
E
S
S

ATM or

H
A
D
L
I
M

ATM

P
u
s
h
T
o
u
c

S
A
M
S
U
N
G
B
I
O

TM efficacy and safety profile.

L

P
I
S
1
0
7
,
C
h
e
o
m
d
a
n
-
d
a
e
r
o
,
Y
e
o
n
s
u
-
g
u
,
I
n
c
h
e

on
,
2
1
9
8
7
,
R
e
p
u
b
l
i
c
o
f
K
o
r
e
a

D
i
s
t
r
i
b
u
t
e
d
b

y
:
M
e
r
c
k
C
a
n
a
d
a
I
n
c
.
K
i
r
k
I
a
n
d
Q
C
C
a
n
a
d
a
H
9
H
4

**D
A
T
E
O
F
I
N
I
T
I
A
L
A
P
P
R
O
V
A
L**

D
e
c
e
m
b
e
r
2
0
,
2
0
1
8

**D
A
T
E
O
F
R
E
V
I
S
I
O
N**

D
e
c
e
m
b
e
r
2
0
,
2
0
1
9

**C
O
N
T
R
O
L
N
U
M
B
E
R**

1
2
3
4
5
6